THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
female patients, \>=18 years of age;
metastatic breast cancer;
HER2 overexpression (IHC 3+ and/or FISH positive);
disease progression during or after previous 1st line chemotherapy plus Herceptin;
scheduled to receive 2nd line chemotherapy.
You may not be if
incompatibility with previous Herceptin therapy;
pregnancy.
Clareo Health | THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
